Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for teva
-0.03 (-0.20%)
Oct 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 14.73 - 14.99
52 week 14.30 - 44.42
Open 14.94
Vol / Avg. 13.29M/24.28M
Mkt cap 14.80B
P/E     -
Div/yield 0.09/7.42
EPS -6.03
Shares 1.02B
Beta 0.57
Inst. own 60%
Nov 2, 2017
Q3 2017 Teva Pharmaceutical Industries Ltd Earnings Call - 8:00AM EDT - Add to calendar
Nov 2, 2017
Q3 2017 Teva Pharmaceutical Industries Ltd Earnings Release - 7:00AM EDT - Add to calendar
Sep 11, 2017
Cooper Companies, Inc. to acquire PARAGARD� Intrauterine Device (IUD) from Teva Pharmaceutical Industries Ltd. - M&A Call - Webcast
Aug 3, 2017
Q2 2017 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Aug 3, 2017
Q2 2017 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -104.75% 1.38%
Operating margin -100.98% 5.80%
EBITD margin - 30.72%
Return on average assets -26.90% 0.41%
Return on average equity -88.38% 0.24%
Employees 56,960 -
CDP Score - A-


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Officers and directors

Sol J. Barer Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Yitzhak Peterburg Interim President and Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Kaare Schultz President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 65
Bio & Compensation  - Reuters
Dipankar Bhattacharjee President and Chief Executive Officer-Global Generic Medicines Group
Age: 56
Bio & Compensation  - Reuters
Carlo de Notaristefani President and Chief Executive Officer-Global Operations
Age: 59
Bio & Compensation  - Reuters
Robert Koremans President, Chief Executive Officer - Global Specialty Medicines
Age: 55
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing & Communication
Age: 51
Bio & Compensation  - Reuters
Hafrun Fridriksdottir Executive Vice President, President of Global Generics R&D
Age: 55
Bio & Compensation  - Reuters
Mark Sabag Group Executive Vice President-Human Resources
Age: 46
Bio & Compensation  - Reuters